The absolute frequency (~10%) of micronuclei in the Rev7−/− cells is similar to that reported for BRCA-deficient cancer cell lines [40], and the approximately three-fold change comparing WT and Rev7 is larger than the fold-induction reported in most studies comparing cancer patients pre- and post-therapy with DNA-damaging agents [41]. Here, MAD2L2 is linked to cancer.